Celcuity to Share Important Findings at Upcoming Symposium
Celcuity Inc. is set to present updated data from its PIK3CA Wild-Type cohort as part of the Phase 3 VIKTORIA-1 clinical trial at a major breast cancer symposium. This annual event, which will take place both virtually and in person, offers an incredible platform for sharing pivotal research findings and advancements in oncology.
Essentials of the Presentation
The abstract detailing these findings has been accepted for an oral presentation session. This will encompass important subgroup efficacy analyses and safety data regarding the use of gedatolisib, a multi-target inhibitor aimed at treating HR+/HER2-/PIK3CA wild-type advanced breast cancer. The presentation is scheduled for December 11, and it features vital insights into recent developments in treatment protocols.
Abstract Details
Abstract Title: Gedatolisib combined with fulvestrant, with or without palbociclib, for second-line treatment in patients dealing with HR+/HER2-/PIK3CA WT advanced breast cancer: updated results from randomized Phase 3 VIKTORIA-1. The session will carry presentation number RF7-04, further enriching the discussions at this symposium.
About Celcuity Inc.
Celcuity Inc., headquartered in Minneapolis, is a dynamic clinical-stage biotechnology company committed to developing targeted therapies to address various solid tumor indications. Its leading therapeutic candidate, gedatolisib, effectively acts as a pan-PI3K and mTORC1/2 inhibitor, serving to hinder the PI3K/AKT/mTOR pathway comprehensively.
Clinical Trials and Future Directions
The efficacy of gedatolisib will be demonstrated through ongoing clinical trials, including VIKTORIA-1, which recently completed enrollment. This study explores the drug's potential when combined with other therapeutic agents such as fulvestrant and palbociclib. Additionally, the VIKTORIA-2 trial is underway, investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as an initial treatment option for patients with HR+/HER2- advanced breast cancer.
Further Information and Updates
Moreover, Celcuity continues to push boundaries in the treatment of metastatic castration-resistant prostate cancer through the ongoing Phase 1/2 clinical trial, CELC-G-201. The company is eager to share updates on both current progress and future research directions as they evolve.
Staying Informed
For additional insights into Celcuity’s active clinical trials, stakeholders and interested parties are encouraged to explore their comprehensive listings on ClinicalTrials.gov. The information will illuminate the potential impacts of their innovative therapies on oncology.
Frequently Asked Questions
What is the main purpose of the presentation at the symposium?
The presentation will share significant updates regarding the efficacy and safety of gedatolisib in treating advanced breast cancer patients.
When is the presentation scheduled?
The oral presentation is scheduled for December 11.
What is Celcuity's primary drug?
Celcuity’s leading drug candidate is gedatolisib, a pan-PI3K and mTORC1/2 inhibitor.
What types of cancer does Celcuity focus on?
Celcuity specializes in targeting solid tumors, including advanced breast cancer and metastatic castration-resistant prostate cancer.
How can I find out more about Celcuity's research?
Comprehensive clinical trial information is available on ClinicalTrials.gov and Celcuity’s official website.